Status:
COMPLETED
Retrospective, Observational, Multi-center Study Evaluating the Efficacy and Tolerance of Brigatinib in the Management of Rearranged CBNPC ROS1
Lead Sponsor:
Centre Hospitalier Intercommunal Creteil
Conditions:
Lung Cancer ROS Translocated
Eligibility:
All Genders
18+ years
Brief Summary
ROS1 translocated Non small cell lung cancer (NSCLC) is a rare type of lung cancer with few datas. We collected datas concerning patients with ROS1 translocated NSCLC who received Brigatinib in the Co...
Detailed Description
Lung cancer is the most common cancer worldwide and the leading cause of cancer death in Western countries. Non-small cell lung cancer (NSCLC) is the most usual form (80-85%) of lung cancers. Unfortun...
Eligibility Criteria
Inclusion
- patient with CBNPC transloated ROS1
- Treatment by Brigatinib as part of compassionate access in France
- Patient \> 18 years old
Exclusion
- Refusal of the patient to participate in this study
Key Trial Info
Start Date :
March 17 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
October 17 2021
Estimated Enrollment :
22 Patients enrolled
Trial Details
Trial ID
NCT04718012
Start Date
March 17 2021
End Date
October 17 2021
Last Update
November 22 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
CHI Créteil
Créteil, France, 94000